These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 30289444)

  • 1. Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048.
    Liu AY; Zhang J; Anderson PL; Wagner T; Pan Z; Peda M; Gomez K; Beamer M; Jacobson C; Strizki J; Dezzutti CS; Piper JM;
    Clin Infect Dis; 2019 Mar; 68(7):1129-1135. PubMed ID: 30289444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings.
    Hoesley CJ; Chen BA; Anderson PL; Dezzutti CS; Strizki J; Sprinkle C; Heard F; Bauermeister J; Hall W; Jacobson C; Berthiaume J; Mayo A; Gundacker H; Richardson-Harman N; Piper J;
    Clin Infect Dis; 2019 Mar; 68(7):1136-1143. PubMed ID: 30289435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial.
    Chen BA; Panther L; Marzinke MA; Hendrix CW; Hoesley CJ; van der Straten A; Husnik MJ; Soto-Torres L; Nel A; Johnson S; Richardson-Harman N; Rabe LK; Dezzutti CS
    J Acquir Immune Defic Syndr; 2015 Nov; 70(3):242-9. PubMed ID: 26034880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women.
    Chen BA; Zhang J; Gundacker HM; Hendrix CW; Hoesley CJ; Salata RA; Dezzutti CS; van der Straten A; Hall WB; Jacobson CE; Johnson S; McGowan I; Nel AM; Soto-Torres L; Marzinke MA;
    Clin Infect Dis; 2019 Mar; 68(7):1144-1151. PubMed ID: 30289485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials.
    Kasserra C; O'Mara E
    Clin Pharmacokinet; 2011 Apr; 50(4):267-80. PubMed ID: 21348539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women.
    Nel A; Haazen W; Nuttall J; Romano J; Rosenberg Z; van Niekerk N
    AIDS; 2014 Jun; 28(10):1479-87. PubMed ID: 24901365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal rings.
    Achilles SL; Kelly CW; Hoesley CJ; Blithe DL; Brown J; Richardson BA; Devlin B; Hendrix CW; Poloyac SM; Marzinke MA; Gundacker H; Singh D; Piper JM; Johnson S; Steytler J; Chen BA;
    PLoS One; 2024; 19(6):e0304552. PubMed ID: 38838028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States.
    Liu AY; Dominguez Islas C; Gundacker H; Neradilek B; Hoesley C; van der Straten A; Hendrix CW; Beamer M; Jacobson CE; McClure T; Harrell T; Bunge K; Devlin B; Nuttall J; Spence P; Steytler J; Piper JM; Marzinke MA;
    J Int AIDS Soc; 2021 Jun; 24(6):e25747. PubMed ID: 34118115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
    Landovitz RJ; Angel JB; Hoffmann C; Horst H; Opravil M; Long J; Greaves W; Fätkenheuer G
    J Infect Dis; 2008 Oct; 198(8):1113-22. PubMed ID: 18783318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States.
    Liu AY; Gundacker H; Richardson B; Chen BA; Hoesley C; van der Straten A; Brown A; Beamer M; Robinson J; Jacobson CE; Scheckter R; Bunge K; Schwartz J; Thurman A; Piper JM; Marzinke MA;
    J Int AIDS Soc; 2024 Mar; 27(3):e26223. PubMed ID: 38444118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen.
    Kasserra C; Sansone-Parsons A; Keung A; Tetteh E; Assaf M; O'Mara E; Marbury T
    Clin Pharmacokinet; 2010 Jun; 49(6):397-406. PubMed ID: 20481650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults.
    Schürmann D; Fätkenheuer G; Reynes J; Michelet C; Raffi F; van Lier J; Caceres M; Keung A; Sansone-Parsons A; Dunkle LM; Hoffmann C
    AIDS; 2007 Jun; 21(10):1293-9. PubMed ID: 17545705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.
    Kasserra C; Li J; March B; O'Mara E
    Clin Ther; 2011 Oct; 33(10):1503-14. PubMed ID: 22015327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
    Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
    AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women.
    Bunge KE; Levy L; Szydlo DW; Zhang J; Gaur AH; Reirden D; Mayer KH; Futterman D; Hoesley C; Hillier SL; Marzinke MA; Hendrix CW; Gorbach PM; Wilson CM; Soto-Torres L; Kapogiannis B; Nel A; Squires KE;
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):135-139. PubMed ID: 31929401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term administration of the CCR5 antagonist vicriviroc to patients with HIV and HCV coinfection is safe and tolerable.
    Fätkenheuer G; Hoffmann C; Slim J; Rouzier R; Keung A; Li J; Treitel M; Sansone-Parsons A; Kasserra C; O'Mara E; Schürmann D
    J Acquir Immune Defic Syndr; 2010 Jan; 53(1):78-85. PubMed ID: 19838130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).
    Robinson JA; Marzinke MA; Bakshi RP; Fuchs EJ; Radebaugh CL; Aung W; Spiegel HM; Coleman JS; Rohan LC; Hendrix CW
    AIDS Res Hum Retroviruses; 2017 Apr; 33(4):339-346. PubMed ID: 27809557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
    Nel AM; Coplan P; Smythe SC; McCord K; Mitchnick M; Kaptur PE; Romano J
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1181-90. PubMed ID: 20854207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Dapivirine Transfer into Blood Plasma, Breast Milk, and Cervicovaginal Fluid of Lactating Women Using the Dapivirine Vaginal Ring.
    Noguchi LM; Hoesley C; Kelly C; Scheckter R; Bunge K; Nel A; Marzinke MA; Hendrix CW; Dezzutti CS; Hillier SL; Bogen DL; Piper JM; Beigi RH
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30602513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.